This clinical trial is focused on studying the effects of a treatment called CagriSema in people with obesity. Obesity is a condition where a person has an excessive amount of body fat, which can increase the risk of other health problems. The treatment being tested combines two substances, cagrilintide and semaglutide, which are given as a solution for injection. These substances are designed to help with weight loss when used alongside a reduced-calorie diet and increased physical activity.

The purpose of the study is to see if CagriSema is more effective than a placebo in helping people with obesity lose weight. Participants in the study will receive injections once a week using a special pen-injector device. The study will last for a period of time, during which participants will be monitored for changes in their body weight and other health indicators. The trial aims to confirm whether CagriSema can lead to significant weight loss and improvements in other health measures compared to those who receive a placebo.

Throughout the study, researchers will track various health outcomes, such as changes in waist size, blood pressure, cholesterol levels, and blood sugar levels. The study will also look at how the treatment affects participants’ overall health and quality of life. The trial is expected to continue for several years to gather comprehensive data on the long-term effects and safety of the treatment. Participants will be closely monitored to ensure their safety and to assess the effectiveness of the treatment in promoting weight loss and improving health.